Interleukin-2 biobetter - Biolingus

Drug Profile

Interleukin-2 biobetter - Biolingus

Alternative Names: SLIT-IL-2-Biolingus

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vitapharm Technology Development
  • Developer Biolingus; Vitapharm Technology Development
  • Class Anti-infectives; Antiallergics; Biobetters; Interleukins; Lymphokines; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Peanut hypersensitivity; Tuberculosis; Type 1 diabetes mellitus
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 12 Sep 2017 Interleukin-2 biobetter - Biolingus is available for licensing as of 12 Sep 2017. http://www.biolingus.ch/index.html#partners
  • 11 Sep 2017 Discontinued - Preclinical for Cancer in China (Sublingual)
  • 11 Sep 2017 Discontinued - Preclinical for Rheumatoid arthritis in China (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top